Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: SLAS Discov. 2021 Apr 24;26(7):922–932. doi: 10.1177/24725552211008853

Figure 1.

Figure 1.

Validation of the isogenic mouse embryonic fibroblast (MEF) panel with a tool compound screen: (A) Sensitivities of 1402 inhibitors were compared between the KRAS-4B-expressing MEF and the HRAS-expressing MEF. (B) Sensitivities of the receptor tyrosine kinase (RTK) inhibitors within the tool compound library were compared among the isogenic MEF panel cell lines. (C) Farnesyl-transferase inhibitors (Lonafarnib, LB42708, and Tipifarnib) dose–response curves for the cell proliferation assay were constructed for the isogenic MEF panel cell lines. (D) AZD217 and (E) vemurafenib and dabrafenib dose–response curves for the cell proliferation assay were constructed for the isogenic MEF panel cell lines.